Page last updated: 2024-08-17

cytidine and molnupiravir

cytidine has been researched along with molnupiravir in 121 studies

Research

Studies (121)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	121 (100.00)	2.80

Authors

Authors	Studies
Hampton, T	1
Hart, M; Natchus, MG; Painter, GR; Plemper, RK; Toots, M; Yoon, JJ	1
Plemper, RK; Toots, M	1
Agostini, ML; Baric, RS; Bluemling, GR; Brown, AJ; Chappell, JD; Denison, MR; Dinnon, KH; George, AS; Graham, RL; Harcourt, J; Hill, CS; Hughes, TM; Kolykhalov, AA; Leist, SR; Lu, X; Montgomery, SA; Natchus, MG; Painter, G; Pruijssers, AJ; Saindane, M; Schäfer, A; Sheahan, TP; Sims, AC; Stevens, LJ; Swanstrom, R; Tamin, A; Thornburg, NJ; Zhou, S	1
Andreou, A; Filippou, D; Sipsas, N; Trantza, S; Tsiodras, S	1
Barfuss, P; Demirbag, S; Khan, KS; Le, TK; Ng, WL; Paris, C; Robson, F; Rocchi, P	1
Shilatifard, A	1
Ahlqvist, GP; Cardoso, FSP; Dietz, JP; Gupton, FB; Jamison, TF; Lucas, T; McGeough, CP; Opatz, T; Paymode, DJ; Snead, DR; Vasudevan, N	1
Govil, A; Luckett, K; Miller-Handley, H	1
Saladini, F; Vicenti, I; Zazzi, M	1
Askin, FB; Baric, RS; Bluemling, GR; Browne, EP; De, C; Dinnon, KH; Garcia, JV; Gralinski, LE; Grant, PO; Gully, K; Johnson, CE; Jones, CD; Kolykhalov, AA; Kovarova, M; Krzystek, HM; Leist, SR; Liu, H; Madden, VJ; Natchus, MG; Painter, G; Pickles, RJ; Schäfer, A; Wahl, A; White, KK; Yao, W; Zaman, T	1
Dolgin, E	1
Barbian, K; Bosio, CM; Feldmann, F; Feldmann, H; Haddock, E; Hansen, F; Hawman, DW; Jarvis, MA; Leventhal, S; Martens, C; Meade-White, K; Okumura, A; Ricotta, E; Rosenke, K; Rosenke, R; Saturday, G; Schwarz, B	1
Reina, J	1
Gordon, CJ; Götte, M; Schinazi, RF; Tchesnokov, EP	1
Bakowski, MA; Beutler, N; Burton, DR; Chatterjee, AK; Chen, E; Chi, V; Das, S; Fuller, M; Garcia, E; Ghosh, P; Gupta, AK; Huang, E; Hull, MV; Joseph, SB; Kirkpatrick, MG; Kuo, P; McNamara, CW; Nguyen, TH; Pan, K; Parren, M; Ricketts, J; Riva, L; Roberts, AJ; Rogers, TF; Sahoo, D; Schultz, PG; Shaabani, N; Teijaro, JR; Vargas, N; Wolff, KC; Woods, AK; Yang, L	1
Menéndez-Arias, L	1
Alexander, LEC; Behroozikhah, M; Beutler, N; Burton, DR; Castillo, V; Claire, A; Crotty, S; Dan, JM; Das, S; Duran, J; Fuller, M; Ghosh, P; Katkar, GD; Khandelwal, S; Pretorius, V; Ramirez, SI; Rawlings, SA; Rogers, TF; Sahoo, D; Smith, DM; Taheri, S; Tindle, C	1
Abdelnabi, R; De Jonghe, S; Foo, CS; Maes, P; Neyts, J; Weynand, B	1
Cohen, O; Holman, W; Natchus, MG; Painter, GR; Painter, WP	1
Cramer, P; Dienemann, C; Hillen, HS; Höbartner, C; Kabinger, F; Kokic, G; Schmitzová, J; Stiller, C	1
Bush, J; Cohen, O; Holman, W; McIntosh, S; Painter, G; Painter, W	1
Amara, A; Else, L; FitzGerald, R; Fletcher, T; Hale, C; Khoo, S; Lyons, R; Penchala, SD; Walker, L	1
Campbell, EA; Malone, B	1
Abdelnabi, R; Augustijns, P; Breuer, J; Chatterjee, AK; Coelmont, L; Dallmeier, K; De Jonghe, S; Do, TND; Foo, CS; Heylen, E; Jochmans, D; Kaptein, SJF; Langendries, L; Leyssen, P; Mols, R; Neyts, J; Pang, J; Vangeel, L; Vergote, V; Weynand, B; Williams, R; Zhang, X	1
Baig, MS; Li, P; Li, Y; Ma, Z; Pan, Q; Peppelenbosch, MP; Solanki, K; Wang, Y	1
Al-Shammeri, AM; Alam, MT; Alaqel, SI; Alhazmi, BD; Alshammari, MK; Alshehri, MM; Alshrari, AS; Asdaq, SMB; Harshan, AA; Imran, M; Khan, SA; Kumar Arora, M; Mateq Ali, A	1
Gill, D; Sidebottom, DB; Smith, DD	1
Tsanni, A	1
van Schalkwyk, JM	1
Couzin-Frankel, J	1
Eloy, P; Guedj, J; Le Grand, R; Malvy, D	1
Dybul, M; Kazatchkine, M; Legido-Quigley, H; Liu, J; Mabuchi, S; Matsoso, P; Nordström, A; Phelan, A; Ramchandani, R; Singh, S; Sudan, P	1
He, G; Huang, W; Zhao, Y	1
Cave, JA; Phizackerley, D	1
Hamblin, MR; Hashemian, SMR; Mirzaei, H; Pourhanifeh, MH; Shahrzad, MK	1
Assaid, C; Brown, ML; Butterton, JR; Caraco, Y; De Anda, C; Delos Reyes, V; Du, J; Gomes da Silva, MM; Gonzalez, A; Grobler, JA; Jayk Bernal, A; Johnson, MG; Kovalchuk, E; Martín-Quirós, A; Musungaie, DB; Paschke, A; Pedley, A; Shamsuddin, HH; Strizki, J; Tipping, R; Wan, H; Williams-Diaz, A	1
Whitley, R	1
Baden, LR; Morrissey, S; Rubin, EJ	1
Alabanza, P; Azizad, MM; Baric, R; Borroto-Esoda, K; Cohen, MS; Coombs, RW; Duke, ER; Eron, JJ; Fang, L; Fischer, WA; Holman, W; James Loftis, A; Lipansky, F; Mollan, KR; Painter, WP; Sheahan, TP; Szewczyk, LJ; Wohl, DA; Wolfe, CR	1
Pourkarim, F; Pourtaghi-Anvarian, S; Rezaee, H	1
Parums, DV	2
Jaeschke, R; Mrukowicz, J; Rochwerg, B	1
Borio, LL; Bright, RA; Emanuel, EJ	1
Hughes, C; Lewis, P; Warren, S; Waters, MD; Zhang, F	1
Del Rio, C; Gandhi, RT; Malani, PN	1
Misra, A; Singh, A; Singh, AK; Singh, R	1
Bruno, MJ; de Vries, AC; Haagmans, BL; Lamers, MM; Lavrijsen, M; Li, P; Pan, Q; Peppelenbosch, MP; Rottier, RJ; Wang, Y	1
Kozlov, M	1
André, E; Chiu, W; De Jonghe, S; Jochmans, D; Leyssen, P; Maes, P; Neyts, J; Raymenants, J; Slechten, B; Vangeel, L	1
Bajaj, SS; Stanford, FC	1
Schinazi, RF; Swanstrom, R	1
Chen, C; Cheng, Y; Feng, Z; Mao, Q; Tang, J; Wang, C; Wang, M; Wen, W; Wu, Q; Zhang, X; Zhou, M; Zhou, X	1
Celik, I; Tallei, TE	1
Babashkina, MG; Burkhanova, TM; Safin, DA; Sharov, AV; Taskın Tok, T	1
Syed, YY	1
B Rouy, S; Entezari-Maleki, T; Khani, E; Khiali, S	1
Ledford, H	1
Brophy, JM	1
Amara, A; Bullock, K; Dickinson, L; Else, L; Ewings, S; FitzGerald, R; Fletcher, T; Greenhalf, W; Griffiths, G; Hale, C; Holman, W; Khoo, S; Lavelle-Langham, L; Lyon, R; Painter, W; Penchala, SD; Reynolds, H; Shaw, V; Walker, L	1
Erdoğan Kablan, S; Eroğlu, H; Karabulut, TC; Kır, S; Nemutlu, E; Neslihan Gürsoy, R; Reçber, T; Timur, SS; Yalçın, F	1
Mills, E; Sheldrick, K; Thorlund, K	1
Abellon-Ruiz, J; Selvi-Sabater, P	1
Levenstein, S	1
Hulstaert, F; Jespers, V; Roberfroid, D	1
De Anda, C; Johnson, MG; Pedley, A	1
Dhama, K; Emran, TB; Frediansyah, A; Harapan, H; Iqhrammullah, M; Masyeni, S; Nainu, F; Ophinni, Y; Tallei, T	1
Abo Elmaaty, A; Al-Karmalawy, AA; Ashour, NA; Elkaeed, EB; Erfan, IA; Moussa, AM; Sarhan, AA	1
Harky, A; Kayali, F; Leung, MST; Morgan, KP; Wong, W	1
Bjork, JA; Wallace, KB	1
Sacks, HS	1
Al-Harrasi, A; El Deeb, S; Ibrahim, AE; Sayed, RA; Sharaf, YA	1
Extance, A	1
Chen, HY; Hu, C; Huang, S; Jia, W; Wang, Y; Zhang, P	1
An, X; Fan, H; Fan, J; Li, M; Lou, F; Pang, Z; Song, L; Tian, L; Tong, Y; Zhu, S	1
Bai, Y; Shen, M; Zhang, L	1
Hama, R	1
Hill, A	1
Hayashi, K	1
Gandhi, RT; Nelson, SB; Razonable, RR; Sendi, P; Soriano, A	1
Adachi, E; Chong, Z; Diamond, MS; Douek, DC; Duong, C; Fujisaki, S; Furusawa, Y; Godbole, S; Gordon, A; Hagihara, M; Halfmann, PJ; Hasegawa, H; Hattori, SI; Hojo, M; Iida, S; Imai, M; Ito, M; Iwatsuki-Horimoto, K; Kawaoka, Y; Kiso, M; Koga, M; Kuroda, M; Larson, D; Li, R; Liu, Y; Loeber, S; Maeda, K; Maemura, T; Mitamura, K; Mitsuya, H; Murakami, J; Ohmagari, N; Okuda, M; Ozono, S; Saito, M; Sakai-Tagawa, Y; Sato, T; Suzuki, T; Takashita, E; Tsutsumi, T; Ueki, H; Ujie, M; Uraki, R; Valdez, R; Wang, Z; Watanabe, S; Wright, R; Yamamoto, S; Yamayoshi, S; Yasuhara, A; Yotsuyanagi, H	1
Bohler, WF; Feldmann, F; Feldmann, H; Griffin, A; Jarvis, MA; Lewis, MC; Meade-White, K; Okumura, A; Rosenke, K; Rosenke, R; Shaia, C	1
Al-Taie, A; Buyuk, AS; Denkdemir, FR; Şardaş, S; Sharief, Z	1
Deeb, SE; Ibrahim, AE; Salman, BI; Saraya, RE	1
Azar, MM; Cohen, E; Malinis, M; Palacios, CF; Radcliffe, C	1
Kulkarni, P; Padmanabhan, S	1
Azeem, S; Cheema, HA; Fatima, M; Saeed, J; Shahid, A	1
Boda, B; Bouveret, M; Constant, S; Engler, OB; Huang, S; Jonsdottir, HR; Julien, T; Padey, B; Pizzorno, A; Rosa-Calatrava, M; Samby, K; Siegrist, D; Terrier, O; Wells, TNC	1
Bassetti, M; Bhagani, S; Brown, ML; Burgess, L; De Anda, C; Duke, ER; Ghosn, J; Johnson, MG; Moncada, PA; Ohmagari, N; Paschke, A; Puenpatom, A; Wan, H; Williams-Diaz, A; Wolf, T; Zhang, Y	1
Cao, R; Chen, X; Dai, Q; Guo, X; Li, W; Li, Y; Liu, M; Wang, Z; Yan, Y; Yang, X; Zhong, W	1
Chow, VTK; Lal, SK; Low, ZY; Yip, AJW	1
Amani, B; Zareei, S	1
Bates, DW; Hua, Y; Jiang, H; Lin, S; Plasek, JM; Yang, J; Zhou, L	1
Alsumali, A; Briggs, A; Cohen, J; Duke, ER; Goswami, H; Jiang, Y; Puenpatom, A; Schindler, M	1
Eades, W; Liu, W; Shen, Y; Yan, B	1
LeBlanc, BW; Santani, BG; Thakare, RP	1
Babudieri, S; Bacciu, S; Bitti, A; Colpani, A; De Vito, A; Denti, L; Fois, M; Madeddu, G; Maida, I; Marcia, C; Meloni, MC; Zauli, B	1
Atmar, RL; Finch, N	1
Cox, RM; Greninger, AL; Juergens, K; Kalykhalov, AA; Lieber, CM; Natchus, MG; Painter, GR; Phung, Q; Plemper, RK; Saindane, MT; Sakamoto, K; Smith, MK; Sourimant, J; Sticher, ZM; Wolf, JD	1
Mahase, E	1
Au, ICH; Cowling, BJ; Lau, EHY; Lau, KTK; Leung, GM; Wong, CKH	1
Kolli, D; Ramakrishna, DS; Seelama, NV; Venkatanarayana, P	1
Beasley, DW; Brasel, T; Comer, JE; Garron, T; Grimes, M; Johnson, DM; Massey, S; Smith, J; Torres, M; Villasante-Tezanos, A; Wallace, S	1
Wise, J	1
Chuang, MH; Hsu, WH; Lai, CC; Liu, TH; Shiau, BW; Tsai, YW; Wu, JY	1
Dhand, A; Kapur, R; Nishida, S; Ohira, S; Okumura, K; Wolfe, K	1
Arvanitis, P; Farmakiotis, D; Guermazi, D	1
Birger, R; Cao, Y; Chawla, A; De Anda, C; Maas, BM; Paschke, A; Rizk, ML; Stone, JA; Wan, H	1
Cao, R; Chen, X; Dai, Q; Guo, X; Li, S; Li, W; Li, Y; Luo, C; Tao, H; Wang, Z; Yan, X; Yang, J; Yang, S; Yang, X; Zhong, W	1
Khoi Quan, N; Linh, NNH; Nguyen, D; Tao, NPH; Tien Huy, N; Tran, NH; Tran, VP	1
Huang, PY; Lai, CC; Liu, TH; Tsai, YW; Wu, JY	1
Huang, C	1
Ahmed, A; Bhardwaj, M; Dhiman, S; Gour, A; Khajuria, P; Manhas, D; Mukherjee, D; Nandi, U; Wazir, P	1
Donovan-Banfield, I; Hartman, H; Hisner, R; Løchen, A; Peacock, TP; Ruis, C; Sanderson, T	1
Baik, SH; Baye, F; Fung, KW; McDonald, CJ	1

Reviews

24 review(s) available for cytidine and molnupiravir

Article	Year
Next-generation direct-acting influenza therapeutics. Translational research : the journal of laboratory and clinical medicine, 2020, Volume: 220 Topics: Amides; Antibodies, Neutralizing; Antiviral Agents; Cytidine; Dibenzothiepins; Drug Resistance, Viral; Humans; Hydroxylamines; Influenza, Human; Morpholines; Neuraminidase; Oxazines; Pyrazines; Pyridines; Pyridones; Ribonucleosides; RNA-Dependent RNA Polymerase; Thiepins; Triazines; Virus Replication	2020
COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2. In vivo (Athens, Greece), 2020, Volume: 34, Issue:3 Suppl Topics: Acetylcysteine; Adenosine Monophosphate; Adjuvants, Immunologic; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Autophagy; Betacoronavirus; Colchicine; Copper; Coronavirus Infections; COVID-19; Cytidine; Drug Synergism; Drug Therapy, Combination; Humans; Hydroxylamines; Inflammation; Nitric Oxide; Pandemics; Pneumonia, Viral; Prodrugs; Ribonucleosides; SARS-CoV-2; Virus Internalization; Virus Replication	2020
Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Molecular cell, 2020, 09-03, Volume: 79, Issue:5 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytidine; Genome, Viral; Humans; Hydroxylamines; Molecular Targeted Therapy; Mutation; Pandemics; Pneumonia, Viral; Pyrazines; Ribonucleosides; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Transcription, Genetic; Viral Nonstructural Proteins; Virus Replication	2020
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. Advances in chronic kidney disease, 2020, Volume: 27, Issue:5 Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Creatinine; Cytidine; Dexamethasone; Drug Combinations; Drug Interactions; Humans; Hydroxychloroquine; Hydroxylamines; Immunization, Passive; Interferons; Janus Kinase Inhibitors; Lopinavir; Pyrazines; Renal Elimination; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ribavirin; Ritonavir; SARS-CoV-2	2020
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert opinion on therapeutic patents, 2021, Volume: 31, Issue:4 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Development; Drug Repositioning; Humans; Hydroxylamines; Pyrazines; RNA-Dependent RNA Polymerase; SARS-CoV-2	2021
[Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2021, Volume: 34, Issue:5 Topics: Animals; Antiviral Agents; COVID-19; Cytidine; Depsipeptides; Humans; Hydroxylamines; Peptide Elongation Factors; Peptides, Cyclic; Ribonucleosides; SARS-CoV-2	2021
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Current opinion in virology, 2021, Volume: 50 Topics: Administration, Oral; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; SARS-CoV-2	2021
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. Molecules (Basel, Switzerland), 2021, Sep-24, Volume: 26, Issue:19 Topics: Administration, Oral; Animals; Antiviral Agents; Clinical Trials as Topic; COVID-19 Drug Treatment; Cytidine; Drug Discovery; Humans; Hydroxylamines; Patents as Topic; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; SARS-CoV-2; Viral Proteins	2021
RdRp inhibitors and COVID-19: Is molnupiravir a good option? Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 146 Topics: Animals; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; RNA-Dependent RNA Polymerase	2022
Molnupiravir: A new candidate for COVID-19 treatment. Pharmacology research & perspectives, 2022, Volume: 10, Issue:1 Topics: Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Interactions; Humans; Hydroxylamines; SARS-CoV-2	2022
Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir. Environmental and molecular mutagenesis, 2022, Volume: 63, Issue:1 Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Deoxyuridine; DNA Damage; Genome, Human; Humans; Hydroxylamines; Mutagenesis; Nucleosides; Pyrazines; Ribavirin; SARS-CoV-2	2022
Molnupiravir in unvaccinated patients with COVID-19. Drug and therapeutics bulletin, 2022, Volume: 60, Issue:3 Topics: COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Humans; Hydroxylamines	2022
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis. Annals of medicine, 2022, Volume: 54, Issue:1 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Fluvoxamine; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2	2022
Molnupiravir: First Approval. Drugs, 2022, Volume: 82, Issue:4 Topics: Adult; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; SARS-CoV-2	2022
Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic. Future microbiology, 2022, Volume: 17 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Pandemics; SARS-CoV-2	2022
Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review. Journal of medical virology, 2022, Volume: 94, Issue:7 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Mutagens; Pandemics; Pharmaceutical Preparations; SARS-CoV-2	2022
A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval. Drug design, development and therapy, 2022, Volume: 16 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Approval; Drug Repositioning; Humans; Hydroxylamines; Microbial Sensitivity Tests; SARS-CoV-2	2022
Molnupiravir and Its Antiviral Activity Against COVID-19. Frontiers in immunology, 2022, Volume: 13 Topics: Animals; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Middle East Respiratory Syndrome Coronavirus; SARS-CoV-2	2022
First-generation oral antivirals against SARS-CoV-2. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:9 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Pharmaceutical Preparations; Ritonavir; SARS-CoV-2	2022
The Long View on COVID-19 Theranostics and Oral Antivirals: Living with Endemic Disease and Lessons from Molnupiravir. Omics : a journal of integrative biology, 2022, Volume: 26, Issue:6 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Endemic Diseases; Humans; Hydroxylamines; Precision Medicine	2022
Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity. Viruses, 2022, 06-20, Volume: 14, Issue:6 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; SARS-CoV-2	2022
Rapid review and meta-analysis of adverse events associated with molnupiravir in patients with COVID-19. British journal of clinical pharmacology, 2022, Volume: 88, Issue:10 Topics: COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines	2022
Response to the letter to the editor on "Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials". Journal of medical virology, 2023, Volume: 95, Issue:7 Topics: COVID-19; Cytidine; Humans; Hydroxylamines; Treatment Outcome	2023
Comment on Huang PS et al. Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials. Med Virol. 2023; 95: e28621. Journal of medical virology, 2023, Volume: 95, Issue:7 Topics: COVID-19; Cytidine; Humans; Hydroxylamines; Treatment Outcome	2023

Trials

7 trial(s) available for cytidine and molnupiravir

Article	Year
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2. Trials, 2021, Aug-23, Volume: 22, Issue:1 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Ribonucleosides; United States	2021
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. The New England journal of medicine, 2022, 02-10, Volume: 386, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Double-Blind Method; Female; Humans; Hydroxylamines; Male; Middle Aged; SARS-CoV-2; Treatment Outcome; Viral Load; Young Adult	2022
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Science translational medicine, 2022, Jan-19, Volume: 14, Issue:628 Topics: Animals; Chlorocebus aethiops; COVID-19; Cytidine; Humans; Hydroxylamines; RNA, Viral; SARS-CoV-2; Treatment Outcome; Vero Cells	2022
An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Diabetes & metabolic syndrome, 2022, Volume: 16, Issue:2 Topics: Adenosine Monophosphate; Aged; Alanine; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Double-Blind Method; Drug Approval; Drug Combinations; Female; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Male; Middle Aged; Nitriles; Proline; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome	2022
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 08-24, Volume: 75, Issue:1 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Nucleosides; Parents; Prodrugs; SARS-CoV-2	2022
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial. Annals of internal medicine, 2022, Volume: 175, Issue:8 Topics: Adult; Biomarkers; COVID-19; Cytidine; Double-Blind Method; Humans; Hydroxylamines; Respiration, Artificial; SARS-CoV-2; Treatment Outcome	2022
Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes. Clinical pharmacology and therapeutics, 2023, Volume: 113, Issue:6 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; SARS-CoV-2	2023

Other Studies

90 other study(ies) available for cytidine and molnupiravir

Article	Year
New Flu Antiviral Candidate May Thwart Drug Resistance. JAMA, 2020, Jan-07, Volume: 323, Issue:1 Topics: Animals; Antiviral Agents; Cytidine; Disease Models, Animal; Drug Resistance, Viral; Humans; Hydroxylamines; Influenza, Human; Macaca; Ribonucleosides	2020
Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Translational research : the journal of laboratory and clinical medicine, 2020, Volume: 218 Topics: Animals; Antiviral Agents; Cytidine; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Viral; Ferrets; HEK293 Cells; Humans; Hydroxylamines; Influenza A virus; Influenza, Human; Madin Darby Canine Kidney Cells; Mutation; Ribonucleosides	2020
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Science translational medicine, 2020, 04-29, Volume: 12, Issue:541 Topics: Adenosine Monophosphate; Alanine; Animals; Antibiotic Prophylaxis; Antiviral Agents; Betacoronavirus; Cell Line; Coronavirus Infections; COVID-19; Cytidine; Disease Models, Animal; Drug Resistance, Viral; Humans; Hydroxylamines; Lung; Mice; Mice, Inbred C57BL; Middle East Respiratory Syndrome Coronavirus; Models, Molecular; Mutation; Pandemics; Pneumonia, Viral; Primary Cell Culture; Random Allocation; Respiratory System; Ribonucleosides; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Virus Replication	2020
COVID-19: Rescue by transcriptional inhibition. Science advances, 2020, Volume: 6, Issue:27 Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytidine; Humans; Hydroxylamines; Pandemics; Pneumonia, Viral; Ribonucleosides; RNA-Dependent RNA Polymerase; SARS-CoV-2; Transcription, Genetic	2020
A concise route to MK-4482 (EIDD-2801) from cytidine. Chemical communications (Cambridge, England), 2020, Nov-11, Volume: 56, Issue:87 Topics: Acylation; Cytidine; Hydroxylamines; Kinetics	2020
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature, 2021, Volume: 591, Issue:7850 Topics: Administration, Oral; Alveolar Epithelial Cells; Animals; Chemoprevention; Chiroptera; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; COVID-19; COVID-19 Drug Treatment; Cytidine; Cytokines; Epithelial Cells; Female; Heterografts; Humans; Hydroxylamines; Immunity, Innate; Interferon Type I; Lung; Lung Transplantation; Male; Mice; Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis; SARS-CoV-2; Virus Replication	2021
The race for antiviral drugs to beat COVID - and the next pandemic. Nature, 2021, Volume: 592, Issue:7854 Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Birds; Clinical Trials as Topic; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Development; Drug Industry; Europe; Humans; Hydroxylamines; Indoles; Influenza, Human; Leucine; Orthomyxoviridae; Pandemics; Pyrrolidinones; Severe Acute Respiratory Syndrome; Strategic Stockpile; United States	2021
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nature communications, 2021, 04-16, Volume: 12, Issue:1 Topics: Administration, Oral; Animals; Antiviral Agents; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Cytidine; Disease Models, Animal; Humans; Hydroxylamines; Mesocricetus; SARS-CoV-2; Vero Cells; Virus Replication	2021
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. The Journal of biological chemistry, 2021, Volume: 297, Issue:1 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Mutagenesis; Point Mutation; RNA, Viral; SARS-CoV-2	2021
Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nature communications, 2021, 06-03, Volume: 12, Issue:1 Topics: Animals; Antiviral Agents; Cell Line; COVID-19; COVID-19 Drug Treatment; Cytidine; Databases, Pharmaceutical; Drug Discovery; Drug Evaluation, Preclinical; Drug Repositioning; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxylamines; Mesocricetus; Nelfinavir; Pandemics; SARS-CoV-2; Virus Replication	2021
Decoding molnupiravir-induced mutagenesis in SARS-CoV-2. The Journal of biological chemistry, 2021, Volume: 297, Issue:1 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Point Mutation; RNA, Viral; SARS-CoV-2	2021
AI-guided discovery of the invariant host response to viral pandemics. EBioMedicine, 2021, Volume: 68 Topics: Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antiviral Agents; Artificial Intelligence; Autopsy; COVID-19; COVID-19 Drug Treatment; Cricetinae; Cytidine; Databases, Genetic; Disease Models, Animal; Gene Expression Profiling; Gene Regulatory Networks; Genetic Markers; Humans; Hydroxylamines; Interleukin-15; Lung; Mesocricetus; Pandemics; Receptors, Interleukin-15; Virus Diseases	2021
Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model. The Journal of infectious diseases, 2021, 09-01, Volume: 224, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cricetinae; Cytidine; Disease Models, Animal; Female; Hydroxylamines; Mutation; Pandemics; SARS-CoV-2; Virus Replication	2021
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nature structural & molecular biology, 2021, Volume: 28, Issue:9 Topics: Animals; Antiviral Agents; Base Sequence; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Models, Molecular; Molecular Structure; Mutagenesis; Mutation; Nucleic Acid Conformation; Protein Binding; Protein Conformation; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Virus Replication	2021
The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva. Journal of pharmaceutical and biomedical analysis, 2021, Nov-30, Volume: 206 Topics: Chromatography, Liquid; COVID-19; Cytidine; Humans; Hydroxylamines; Reproducibility of Results; Saliva; SARS-CoV-2; Tandem Mass Spectrometry	2021
Molnupiravir: coding for catastrophe. Nature structural & molecular biology, 2021, Volume: 28, Issue:9 Topics: Antiviral Agents; Base Pairing; COVID-19 Drug Treatment; Cytidine; DNA-Directed RNA Polymerases; Genes, Lethal; Genome, Viral; Humans; Hydroxylamines; Molecular Structure; Mutagenesis; Nucleic Acid Conformation; RNA, Viral; SARS-CoV-2; Substrate Specificity; Templates, Genetic; Virus Replication	2021
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. EBioMedicine, 2021, Volume: 72 Topics: Amides; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Disease Models, Animal; Drug Therapy, Combination; Female; Hydroxylamines; Lung; Mesocricetus; Pyrazines; RNA, Viral; Treatment Outcome; Viral Load	2021
Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses. Virology, 2021, Volume: 564 Topics: Antiviral Agents; Common Cold; Coronavirus 229E, Human; Coronavirus Infections; Coronavirus NL63, Human; Coronavirus OC43, Human; Cytidine; Humans; Hydroxylamines; Molecular Docking Simulation; Protein Binding; Pyrrolidines; RNA-Dependent RNA Polymerase; Seasons; Sulfonic Acids; Virus Replication	2021
Unmet need for COVID-19 therapies in community settings. The Lancet. Infectious diseases, 2021, Volume: 21, Issue:11 Topics: Adenosine Monophosphate; Alanine; Ambulatory Care; Antibodies, Monoclonal; Antiviral Agents; Community Health Services; COVID-19; COVID-19 Vaccines; Cytidine; Drug Combinations; Health Services Needs and Demand; Humans; Hydroxylamines; Socioeconomic Factors; Treatment Outcome; Viral Load	2021
Safety and efficacy of antivirals against SARS-CoV-2. BMJ (Clinical research ed.), 2021, 10-28, Volume: 375 Topics: Advisory Committees; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Evidence-Based Medicine; Humans; Hydroxylamines; Pandemics; SARS-CoV-2	2021
African scientists race to test COVID drugs - but face major hurdles. Nature, 2021, Volume: 599, Issue:7883 Topics: Africa; Amides; Amodiaquine; Artesunate; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Approval; Drug Evaluation, Preclinical; Drug Repositioning; Drug Therapy, Combination; Humans; Hydroxylamines; Imidazoles; Ivermectin; Naphthyridines; Nitro Compounds; Pregnenediones; Pyrazines; Pyrrolidines; Ritonavir; Sample Size; Thiazoles; Valine; World Health Organization	2021
Buyer beware: molnupiravir may damage DNA. BMJ (Clinical research ed.), 2021, 11-04, Volume: 375 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; DNA Damage; Humans; Hydroxylamines; SARS-CoV-2	2021
Antiviral pills could change pandemic's course. Science (New York, N.Y.), 2021, Nov-12, Volume: 374, Issue:6569 Topics: Antiviral Agents; Clinical Trials as Topic; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2; Tablets	2021
Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two? EBioMedicine, 2021, Volume: 74 Topics: Amides; Animals; Antiviral Agents; COVID-19 Drug Treatment; Cricetinae; Cytidine; Drug Synergism; Drug Therapy, Combination; Humans; Hydroxylamines; Pyrazines; SARS-CoV-2	2021
Vaccines, therapeutics, and diagnostics for covid-19: redesigning systems to improve pandemic response. BMJ (Clinical research ed.), 2021, 11-28, Volume: 375 Topics: Antiviral Agents; Communicable Disease Control; COVID-19; COVID-19 Vaccines; Cytidine; Global Health; Health Policy; Health Services Accessibility; Humans; Hydroxylamines; Oxygen Inhalation Therapy; Pandemics; Public Health; SARS-CoV-2; World Health Organization	2021
A novel model of molnupiravir against SARS-CoV-2 replication: accumulated RNA mutations to induce error catastrophe. Signal transduction and targeted therapy, 2021, 12-02, Volume: 6, Issue:1 Topics: COVID-19; Cytidine; Humans; Hydroxylamines; Mutation; RNA; SARS-CoV-2	2021
Molnupiravir: evidence by press release. Drug and therapeutics bulletin, 2022, Volume: 60, Issue:1 Topics: Cytidine; Humans; Hydroxylamines	2022
Molnupiravir - A Step toward Orally Bioavailable Therapies for Covid-19. The New England journal of medicine, 2022, 02-10, Volume: 386, Issue:6 Topics: COVID-19; Cytidine; Humans; Hydroxylamines; SARS-CoV-2	2022
Audio Interview: A Potential New Agent to Treat Covid-19. The New England journal of medicine, 2021, Dec-23, Volume: 385, Issue:26 Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Anti-Inflammatory Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Evolution, Molecular; Hospitalization; Humans; Hydroxylamines; Mutagenesis; Risk Assessment; SARS-CoV-2; Time-to-Treatment; Vaccine Efficacy; Viral Load; Virus Replication	2021
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients. Medical science monitor : international medical journal of experimental and clinical research, 2022, Jan-01, Volume: 28 Topics: Administration, Oral; Antibodies, Monoclonal; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Approval; Drug Repositioning; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2; United States; United States Food and Drug Administration	2022
Will molnupiravir be a game changer in our efforts to safe COVID-19 outpatients? Polish archives of internal medicine, 2022, 01-28, Volume: 132, Issue:1 Topics: COVID-19; Cytidine; Humans; Hydroxylamines; Outpatients; SARS-CoV-2	2022
A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics. JAMA, 2022, Jan-18, Volume: 327, Issue:3 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; COVID-19 Vaccines; Cytidine; Drug Combinations; Endemic Diseases; Humans; Hydroxylamines; Immunization Schedule; Lactams; Leucine; Nitriles; Population Surveillance; Proline; Ritonavir; SARS-CoV-2; United States	2022
COVID is here to stay: countries must decide how to adapt. Nature, 2022, Volume: 601, Issue:7892 Topics: Adaptation, Psychological; Adult; Child; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Combinations; Endemic Diseases; Humans; Hydroxylamines; Immunity, Herd; Immunization, Secondary; International Cooperation; Lactams; Leucine; Nitriles; Physical Distancing; Proline; Reinfection; Ritonavir; SARS-CoV-2; Social Change; South Africa	2022
COVID-19 Therapeutics for Nonhospitalized Patients. JAMA, 2022, 02-15, Volume: 327, Issue:7 Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; Child; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Female; Health Care Rationing; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Outpatients; Pregnancy; Proline; Ritonavir	2022
SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell research, 2022, Volume: 32, Issue:3 Topics: COVID-19; Cytidine; Humans; Hydroxylamines; SARS-CoV-2	2022
Why scientists are racing to develop more COVID antivirals. Nature, 2022, Volume: 601, Issue:7894 Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Approval; Drug Combinations; Drug Development; Drug Resistance, Viral; Drug Therapy, Combination; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Medication Adherence; Molecular Targeted Therapy; Mutagenesis; Nitriles; Proline; Public-Private Sector Partnerships; Research Personnel; Ritonavir; SARS-CoV-2	2022
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral research, 2022, Volume: 198 Topics: Adenosine; Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Lactams; Leucine; Microbial Sensitivity Tests; Nitriles; Proline; RNA-Dependent RNA Polymerase; SARS-CoV-2; Vero Cells; Virus Replication	2022
COVID-19: LMICs need antivirals as well as vaccines. Nature, 2022, Volume: 602, Issue:7895 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Developed Countries; Developing Countries; Drug Costs; Healthcare Disparities; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Licensure; Nitriles; Proline	2022
Lethal mutagenesis as an antiviral strategy. Science (New York, N.Y.), 2022, Feb-04, Volume: 375, Issue:6580 Topics: Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; DNA; Evolution, Molecular; Genome, Viral; Humans; Hydroxylamines; Mutagenesis; Mutagenicity Tests; Phosphorylation; Ribonucleosides; RNA Virus Infections; RNA Viruses; RNA, Viral; SARS-CoV-2	2022
A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA-dependent RNA polymerase of wild-type and Delta subvariant AY.4 of SARS-CoV-2. Journal of cellular biochemistry, 2022, Volume: 123, Issue:4 Topics: Animals; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Mammals; Molecular Docking Simulation; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2	2022
Molnupiravir for treatment of COVID-19. The Medical letter on drugs and therapeutics, 2022, Jan-24, Volume: 64, Issue:1642 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Approval; Drug Interactions; Humans; Hydroxylamines; Treatment Outcome; United States; United States Food and Drug Administration	2022
Treatment of COVID-19 in high-risk outpatients. The Medical letter on drugs and therapeutics, 2022, Feb-07, Volume: 64, Issue:1643 Topics: Adenosine Monophosphate; Alanine; Ambulatory Care; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Outpatients; Proline; Ritonavir; Treatment Outcome	2022
Computational Analysis of Molnupiravir. International journal of molecular sciences, 2022, 01-28, Volume: 23, Issue:3 Topics: Antiviral Agents; Computational Biology; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Molecular Docking Simulation; Protein Binding; SARS-CoV-2	2022
Hundreds of COVID trials could provide a deluge of new drugs. Nature, 2022, Volume: 603, Issue:7899 Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Depsipeptides; Dexamethasone; Drug Combinations; Drug Repositioning; Drug Synergism; Esters; Guanidines; Hospitalization; Host-Pathogen Interactions; Humans; Hydroxylamines; Internationality; Lactams; Leucine; Mice; National Institutes of Health (U.S.); Nitriles; Peptide Elongation Factor 1; Peptides, Cyclic; Proline; Protease Inhibitors; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Serine Endopeptidases; Sodium-Glucose Transporter 2 Inhibitors; United States; Virus Replication	2022
Molnupiravir's authorisation was premature. BMJ (Clinical research ed.), 2022, 03-03, Volume: 376 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Approval; Humans; Hydroxylamines; SARS-CoV-2	2022
A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies. Journal of pharmaceutical and biomedical analysis, 2022, May-30, Volume: 214 Topics: Caco-2 Cells; Chromatography, High Pressure Liquid; COVID-19 Drug Treatment; Cytidine; Drug Stability; Humans; Hydroxylamines; Permeability; Pharmaceutical Preparations; Reproducibility of Results; SARS-CoV-2	2022
Molnupiravir for Covid-19 in Nonhospitalized Patients. The New England journal of medicine, 2022, 03-31, Volume: 386, Issue:13 Topics: COVID-19; Cytidine; Humans; Hydroxylamines	2022
Molnupiravir for Covid-19 in Nonhospitalized Patients. The New England journal of medicine, 2022, 03-31, Volume: 386, Issue:13 Topics: COVID-19; Cytidine; Humans; Hydroxylamines	2022
Molnupiravir for Covid-19 in Nonhospitalized Patients. The New England journal of medicine, 2022, 03-31, Volume: 386, Issue:13 Topics: COVID-19; Cytidine; Humans; Hydroxylamines	2022
Molnupiravir for Covid-19 in Nonhospitalized Patients. The New England journal of medicine, 2022, 03-31, Volume: 386, Issue:13 Topics: COVID-19; Cytidine; Humans; Hydroxylamines	2022
Molnupiravir for Covid-19 in Nonhospitalized Patients. Reply. The New England journal of medicine, 2022, 03-31, Volume: 386, Issue:13 Topics: COVID-19; Cytidine; Humans; Hydroxylamines	2022
What impact can molnupiravir have on the treatment of SARS-CoV-2 infection? Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:8 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; SARS-CoV-2	2022
Molnupiravir; molecular and functional descriptors of mitochondrial safety. Toxicology and applied pharmacology, 2022, 05-01, Volume: 442 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Mitochondria; Nucleosides; RNA; SARS-CoV-2	2022
In nonhospitalized, unvaccinated adults with COVID-19, molnupiravir reduced hospitalization or death at 29 d. Annals of internal medicine, 2022, Volume: 175, Issue:4 Topics: Adult; COVID-19; Cytidine; Hospitalization; Humans; Hydroxylamines; SARS-CoV-2	2022
Two Green Micellar HPLC and Mathematically Assisted UV Spectroscopic Methods for the Simultaneous Determination of Molnupiravir and Favipiravir as a Novel Combined COVID-19 Antiviral Regimen. Molecules (Basel, Switzerland), 2022, Apr-04, Volume: 27, Issue:7 Topics: Amides; Antiviral Agents; Chromatography, High Pressure Liquid; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Micelles; Pandemics; Pyrazines; Reproducibility of Results; SARS-CoV-2; Spectrophotometry, Ultraviolet	2022
Covid-19: What is the evidence for the antiviral molnupiravir? BMJ (Clinical research ed.), 2022, 04-13, Volume: 377 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines	2022
A Nanopore Based Molnupiravir Sensor. ACS sensors, 2022, 05-27, Volume: 7, Issue:5 Topics: COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Nanopores; Nucleosides; SARS-CoV-2	2022
Antiviral Efficacy of Molnupiravir for COVID-19 Treatment. Viruses, 2022, 04-06, Volume: 14, Issue:4 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Pandemics; SARS-CoV-2	2022
Imbalance in baseline characteristics in molnupiravir trials. BMJ (Clinical research ed.), 2022, 04-26, Volume: 377 Topics: Cytidine; Humans; Hydroxylamines; Ownership	2022
Molnupiravir's authorisation should be re-evaluated after the Panoramic trial is reported. BMJ (Clinical research ed.), 2022, 04-26, Volume: 377 Topics: Cytidine; Drug Approval; Humans; Hydroxylamines	2022
Molnupiravir might be dangerous without clarification of its indications. BMJ (Clinical research ed.), 2022, 04-26, Volume: 377 Topics: Cytidine; Humans; Hydroxylamines	2022
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature, 2022, Volume: 607, Issue:7917 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cricetinae; Cytidine; Drug Combinations; Hydroxylamines; Indazoles; Lactams; Leucine; Mice; Nitriles; Proline; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Triazines; Triazoles	2022
Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model. JCI insight, 2022, 07-08, Volume: 7, Issue:13 Topics: Animals; COVID-19 Drug Treatment; Cricetinae; Cytidine; Humans; Hydroxylamines; SARS-CoV-2	2022
Highly sensitive high-performance thin-layer chromatography method for the simultaneous determination of molnupiravir, favipiravir, and ritonavir in pure forms and pharmaceutical formulations. Journal of separation science, 2022, Volume: 45, Issue:14 Topics: Amides; Antiviral Agents; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; COVID-19 Drug Treatment; Cytidine; Drug Compounding; Humans; Hydroxylamines; Pyrazines; Reproducibility of Results; Ritonavir; SARS-CoV-2	2022
Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2022, Volume: 22, Issue:10 Topics: Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; COVID-19; COVID-19 Testing; Cytidine; Female; Humans; Hydroxylamines; Male; Middle Aged; Organ Transplantation; Ritonavir; SARS-CoV-2; Transplant Recipients	2022
A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19. Biotechnology letters, 2022, Volume: 44, Issue:7 Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Deoxyglucose; Hexokinase; Humans; Hydroxylamines; Molecular Docking Simulation; Pyrazines; SARS-CoV-2	2022
Efficacy and safety of molnupiravir for COVID-19 patients. European journal of internal medicine, 2022, Volume: 102 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines	2022
Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 150 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Nasal Mucosa; SARS-CoV-2	2022
Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo. Viruses, 2022, 05-25, Volume: 14, Issue:6 Topics: Animals; Antigens, Viral; Antiviral Agents; Child, Preschool; COVID-19; Cytidine; Enterovirus; Enterovirus A, Human; Enterovirus Infections; Humans; Hydroxylamines; Mice; Mice, Inbred ICR	2022
Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications. Journal of the American Medical Informatics Association : JAMIA, 2022, 09-12, Volume: 29, Issue:10 Topics: COVID-19 Drug Treatment; Cytidine; Delivery of Health Care; Humans; Hydroxychloroquine; Hydroxylamines; Ivermectin; Off-Label Use; Pandemics; Public Opinion; Retrospective Studies; Social Media	2022
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US. PharmacoEconomics, 2022, Volume: 40, Issue:7 Topics: Adult; Cost-Benefit Analysis; COVID-19; Cytidine; Humans; Hydroxylamines; Male; Outpatients; Prostate-Specific Antigen; Quality-Adjusted Life Years	2022
The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro. Drug metabolism and disposition: the biological fate of chemicals, 2022, Volume: 50, Issue:9 Topics: Carboxylesterase; Carboxylic Ester Hydrolases; COVID-19 Drug Treatment; Cytidine; Drug Interactions; Humans; Hydrolysis; Hydroxylamines; Molecular Docking Simulation; Pharmaceutical Preparations; Polymorphism, Genetic	2022
Molnupiravir for the treatment of COVID-19. Drugs of today (Barcelona, Spain : 1998), 2022, Volume: 58, Issue:7 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; SARS-CoV-2; United States	2022
Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience. Journal of medical virology, 2022, Volume: 94, Issue:11 Topics: Aged; Aged, 80 and over; COVID-19 Drug Treatment; Cytidine; Disease Progression; Humans; Hydroxylamines; Middle Aged; Retrospective Studies; SARS-CoV-2	2022
New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19. Antimicrobial agents and chemotherapy, 2022, 08-16, Volume: 66, Issue:8 Topics: Anti-Infective Agents; Antiviral Agents; Child; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Ritonavir; SARS-CoV-2	2022
SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model. Nature communications, 2022, 07-29, Volume: 13, Issue:1 Topics: Animals; COVID-19 Drug Treatment; Cricetinae; Cytidine; Ferrets; Humans; Hydroxylamines; Lung; Male; SARS-CoV-2	2022
Covid-19: Results from India's 12 molnupiravir clinical trials remain unpublished. BMJ (Clinical research ed.), 2022, 08-19, Volume: 378 Topics: Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; India	2022
Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir. Medical science monitor : international medical journal of experimental and clinical research, 2022, Oct-01, Volume: 28 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2	2022
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: a Lancet (London, England), 2022, 10-08, Volume: 400, Issue:10359 Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Disease Progression; Hong Kong; Hospital Mortality; Hospitalization; Humans; Hydroxylamines; Independent Living; Retrospective Studies; Ritonavir; SARS-CoV-2	2022
Synthesis of molnupiravir (MK-4482, EIDD-2801): a promising oral drug for the treatment of COVID-19 starting from cytidine. Nucleosides, nucleotides & nucleic acids, 2023, Volume: 42, Issue:6 Topics: Acylation; Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines	2023
Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model. Antiviral research, 2023, Volume: 209 Topics: Animals; COVID-19; Cytidine; Macaca mulatta; SARS-CoV-2	2023
Covid-19: Molnupiravir does not cut hospital admissions or deaths in vaccinated people at high risk, trial finds. BMJ (Clinical research ed.), 2022, 12-23, Volume: 379 Topics: Antiviral Agents; COVID-19; Cytidine; Hospitals; Humans; Hydroxylamines	2022
The effect of molnupiravir on post-acute outcome of COVID-19 survivors. The Journal of infection, 2023, Volume: 87, Issue:4 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines	2023
Molnupiravir for Treatment of COVID-19 in Solid Organ Transplant Recipients. Transplantation, 2023, 06-01, Volume: 107, Issue:6 Topics: COVID-19; Cytidine; Humans; Hydroxylamines; Organ Transplantation; Transplant Recipients	2023
Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept. Infection, 2023, Volume: 51, Issue:5 Topics: Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Immunocompromised Host	2023
In vitro and in vivo efficacy of Molnupiravir against Zika virus infections. Virologica Sinica, 2023, Volume: 38, Issue:4 Topics: Antiviral Agents; Cytidine; Humans; Hydroxylamines; Zika Virus; Zika Virus Infection	2023
Molnupiravir as the COVID-19 panacea: false beliefs in low- and middle-income countries. Pathogens and global health, 2023, Volume: 117, Issue:6 Topics: Antiviral Agents; COVID-19; Cytidine; Developing Countries; Humans; Hydroxylamines	2023
Impact of Disease States on the Oral Pharmacokinetics of EIDD-1931 (an Active Form of Molnupiravir) in Rats for Implication in the Dose Adjustment. Molecular pharmaceutics, 2023, 09-04, Volume: 20, Issue:9 Topics: Animals; COVID-19; Cytidine; Hydroxylamines; Rats	2023
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes. Nature, 2023, Volume: 623, Issue:7987 Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Evolution, Molecular; Genome, Viral; Humans; Hydroxylamines; Mutagenesis; Mutation; Phylogeny; SARS-CoV-2; Viral Load; Virus Replication	2023
Nirmatrelvir and Molnupiravir and Post-COVID-19 Condition in Older Patients. JAMA internal medicine, 2023, Dec-01, Volume: 183, Issue:12 Topics: Aged; Antiviral Agents; COVID-19; Cytidine; Humans; Hydroxylamines; Lactams; Nitriles	2023